Key insights
- An analyst anticipates increased takeover potential for Lionsgate (LGF) after its poison pill expires in May 2026. The pure-play studio assets and post-spinoff structure make it an attractive target. The analyst is accumulating shares, expecting upside potential driven by the release of the movie "MICHAEL" in April 2026 and a potential sale or strategic partnership. They estimate the company's value at $17-20 per share.
Once the poison pill at Lionsgate Studios expires (May 7, 2026), the dynamics around control of the company change pretty materially. By June 2026, An activist or buyer can build a position quickly in the open market, No automatic dilution penalty kicks, and board can no longer stop the takeover as easily.
Expected scenarios post release of MICHAEL blockbuster in April 2026 and expiry of poison pill in May 2026:
- Sale of the studio * Strategic partnerships/streaming deals * Cost cuts or capital return
Lionsgate primed for takeover:
- Pure-play studio assets are easier to value/sell * Post-spinoff structure = fewer legacy protections * Content library = very attractive to buyers
Lionsgate has drawn down with the rest of the market this past week; however, the upside SEVERELY outweighs downside at this very juncture.
We will continue acquiring; adding 50,000 shares in past 5 days, and will build into the release of MICHAEL, the movie. We price EV inclusive of debt at approximately $17-20 a share as of this week.